<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02404935</url>
  </required_header>
  <id_info>
    <org_study_id>Prodige 28 - UCGI 27 (TIME)</org_study_id>
    <secondary_id>2012-005139-99</secondary_id>
    <nct_id>NCT02404935</nct_id>
  </id_info>
  <brief_title>Treatment After Irinotecan-based Frontline Therapy: Maintenance With Erbitux (in Patients wtRAS mCRC)</brief_title>
  <acronym>TIME</acronym>
  <official_title>Randomized Phase II Study of First-line FOLFIRI Plus Cetuximab for 8 Cycles Followed by Either Single-agent Cetuximab as Maintenance Therapy or Observation in Patients With Wild-type KRAS and NRAS Metastatic Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UNICANCER</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UNICANCER</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      National multicentric phase II trial evaluating whether single agent cetuximab is effective
      as maintenance therapy after 8 cycles of first line FOLFIRI plus cetuximab in mCRC patients
      with KRAS and NRAS wild-type genes, assessed by progression-free survival at 6 months after
      start of maintenance therapy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">February 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate whether single agent cetuximab is effective as maintenance therapy after 8 cycles of first line FOLFIRI plus cetuximab (Progression Free Survival)</measure>
    <time_frame>6 months after start of maintenance therapy</time_frame>
    <description>Progression Free Survival (PFS) at 6 months after start of maintenance therapy defined as the number of patients at 6 months from the date of randomization without documented progression or death from any cause. Progression will be assessed by CT scan according to RECIST criteria version 1.1</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">168</enrollment>
  <condition>Metastatic Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A cetuximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>cetuximab 500 mg/m2 (every 2 weeks) until progression</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B observation</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>observation until progression</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetuximab</intervention_name>
    <arm_group_label>Arm A cetuximab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFIRI and cetuximab</intervention_name>
    <arm_group_label>Arm A cetuximab</arm_group_label>
    <arm_group_label>Arm B observation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically confirmed colorectal cancer

          2. KRAS and NRAS wild-type genes after analysis of mutation status from the primary
             tumour or metastasis

          3. Non resectable metastatic disease in a curative intent

          4. No prior chemotherapy except for fluoropyrimidines with or without oxaliplatin-based
             adjuvant treatment earlier than 6 months ago from inclusion date

          5. Patient presenting with at least one measurable tumour target (greater than 20 mm)
             according to RECIST criteria, which has never been irradiated

          6. Patient with a greater than 3 month life expectancy

          7. Performance Status less or equal to 2

          8. Male or female 18 years or older

          9. Acceptable blood test

         10. Patient who has signed a written informed consent form

        Exclusion Criteria:

          1. Known and/or symptomatic brain metastases

          2. Known allergy to one of treatment components

          3. Neurological or psychiatric condition which could interfere with good treatment
             compliance

          4. Patient currently in treatment with any other anti-tumour therapy: chemotherapy or
             targeted therapy or radiotherapy ≤ 14 days before randomisation

          5. Other serious conditions such as: respiratory failure. History of interstitial lung
             disease e.g. pneumonitis or pulmonary fibrosis or evidence of interstitial lung
             disease on baseline chest CT scan.

          6. Clinically significant cardiovascular disease (including myocardial infarction,
             unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac
             arrhythmia) 6 months before enrolment/randomisation

          7. Concomitant severe infection.

          8. History of cancer (except skin cancer other than melanoma or an in situ cervical
             epithelioma or other solid tumour treated for curative purposes without signs of the
             condition and with no treatment administered in the 5 years before randomisation.)

          9. Patient already included in another clinical trial with an investigational molecule

         10. Prior treatment with anti-EGFr antibodies (e.g. panitumumab (Vectibix® or cetuximab /
             Erbitux® ) or treatment with small EGFr inhibitor molecules (e.g., erlotinib /
             Tarceva®)

         11. Pregnant female, likely to be or currently breast feeding, or planning to become
             pregnant within 6 months after the end of treatment or absence of effective
             contraception for males and females of childbearing age during treatment and for 6
             months (male or female) after the end of treatment

         12. Those deprived of their freedom or under guardianship

         13. Impossibility of undergoing trial's medical follow-up for geographical, social or
             psychological reasons
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sandra PELISSIER</last_name>
    <phone>+33 (0)1 44 23 55 68</phone>
    <email>s-pelissier@unicancer.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <state>Ile de France</state>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valérie Boige</last_name>
      <phone>+33 1 42 11 42 89</phone>
      <email>valerie.boige@gustaveroussy.fr</email>
    </contact>
    <investigator>
      <last_name>Valérie BOIGE, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU- Hôpital Sud</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vincent Hautefeuille</last_name>
      <phone>+ 33 2 22 66 82 00</phone>
      <email>hautefeuille.vincent@chu-amiens.fr</email>
    </contact>
    <investigator>
      <last_name>Vincent HAUTEFEUILLE, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire d'Angers</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier d'Auxerre</name>
      <address>
        <city>Auxerre</city>
        <zip>89011</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne-Laure Villing</last_name>
      <phone>+33 3 86 48 47 13</phone>
      <email>alvilling@ch-auxerre.fr</email>
    </contact>
    <investigator>
      <last_name>Anne-Laure VILLING, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Sainte Catherine</name>
      <address>
        <city>Avignon</city>
        <zip>84918</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurent Mineur</last_name>
      <phone>+33 4 90 27 62 68</phone>
      <email>l.mineur@isc84.org</email>
    </contact>
    <investigator>
      <last_name>Laurent MINEUR, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Intercommunal Cote Basque</name>
      <address>
        <city>Bayonne</city>
        <zip>64109</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Franck Audemar</last_name>
      <phone>+ 33 5 59 44 37 22</phone>
      <email>faudemar@ch-cotebasque.fr</email>
    </contact>
    <investigator>
      <last_name>Franck AUDEMAR, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Beauvais</name>
      <address>
        <city>Beauvais</city>
        <zip>60021</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Faycal Hocine</last_name>
      <phone>+33 3 44 11 21 22</phone>
      <email>fayoncologie@yahoo.fr</email>
    </contact>
    <investigator>
      <last_name>Faycal HOCINE, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Blois</name>
      <address>
        <city>Blois</city>
        <zip>41000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Avicenne</name>
      <address>
        <city>Bobigny</city>
        <zip>93009</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Aparicio</last_name>
      <phone>+33 1 40 25 72 00</phone>
      <email>thomas.aparicio@avc.aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinqiue Tivoli</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nathalie Bonichon Lamichhane</last_name>
      <phone>+ 33 5 56 11 60 87</phone>
      <email>bonichon-lamichhane@wanadoo.fr</email>
    </contact>
    <investigator>
      <last_name>Nathalie BONICHON LAMICHHANE, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Bergonie</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dominique Bechade</last_name>
      <phone>+33 5 56 33 32 65</phone>
      <email>d.bechade@bordeaux.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Dominique BECHADE, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Béziers</name>
      <address>
        <city>Béziers</city>
        <zip>34500</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre François Baclesse</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie-Pierre Galais</last_name>
      <phone>+33 2 31 45 52 71</phone>
      <email>mp.gallais@baclesse.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Marie-Pierre GALAIS, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Côte de nacre</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Jean Rougier</name>
      <address>
        <city>Cahors</city>
        <zip>46000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nadia Djabali Levasseur</last_name>
      <phone>+33 5 65 20 50 21</phone>
      <email>nadia.levasseur@ch-cahors.fr</email>
    </contact>
    <investigator>
      <last_name>Nadia DJABALI LEVASSEUR, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Estaing</name>
      <address>
        <city>Clermont Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caroline Petorin</last_name>
      <phone>+33 4 73 75 05 08</phone>
      <email>cpetorin@chu-clermontferrand.fr</email>
    </contact>
    <investigator>
      <last_name>Caroline PETORIN, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital du Bocage</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Louis Jouve</last_name>
      <phone>+ 33 3 80 29 37 50</phone>
      <email>jean-louis.jouve@chu-dijon.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-Louis JOUVE, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de la Dracénie</name>
      <address>
        <city>Draguignan</city>
        <zip>83007</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinique du Mousseau</name>
      <address>
        <city>Evry</city>
        <zip>91035</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Intercommunal</name>
      <address>
        <city>Frejus</city>
        <zip>83007</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier Départemental de Vendée - Les Oudairies</name>
      <address>
        <city>La Roche Sur Yon</city>
        <zip>85925</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roger Faroux</last_name>
      <phone>+33 2 51 44 61 68</phone>
      <email>roger.faroux@chd-vendee.fr</email>
    </contact>
    <investigator>
      <last_name>Roger FAROUX, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique du Cap d'Or</name>
      <address>
        <city>La Seyne Sur Mer</city>
        <zip>83500</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Bicêtre</name>
      <address>
        <city>Le Kremlin Bicêtre</city>
        <zip>94275</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Farid El Hajbi</last_name>
      <phone>+33 3 20 29 59 42</phone>
      <email>f-elhajbi@o-lambret.fr</email>
    </contact>
    <investigator>
      <last_name>Farid EL HAJBI, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique Francois Chenieux</name>
      <address>
        <city>Limoges</city>
        <zip>87039</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dominique Genet</last_name>
      <phone>+33 5 55 45 48 00</phone>
      <email>dg@imagemed-87.com</email>
    </contact>
    <investigator>
      <last_name>Dominique GENET, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Limoges - Hôpital Dupuytren</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valérie Le Brun-Ly</last_name>
      <phone>+ 33 5 55 05 63 96</phone>
      <email>valerie.lebrun@chu-limoges.fr</email>
    </contact>
    <investigator>
      <last_name>Valérie LE BRUN-LY, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christelle De La Fouchardière</last_name>
      <phone>+33 4 78 78 27 51</phone>
      <email>christelle.delafouchardire@lyon.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Christelle DE LA FOUCHARDIERE, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital de La Timone</name>
      <address>
        <city>Marseille</city>
        <zip>13005</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laëtita Dahan</last_name>
      <phone>+33 4 91 38 60 23</phone>
      <email>laetitia.dahan@ap-hm.fr</email>
    </contact>
    <investigator>
      <last_name>Laëtita DAHAN, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Privé Clairval</name>
      <address>
        <city>Marseille</city>
        <zip>13009</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean Luc Raoul</last_name>
      <phone>+33 4 91 22 37 78</phone>
      <email>raouljl@ipc.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Jean Luc RAOUL, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Montelimar</name>
      <address>
        <city>Montelimar</city>
        <zip>26216</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre de Cancérologie du Grand Montepellier - Clinique Clementville</name>
      <address>
        <city>Montpellier</city>
        <zip>34070</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut régional du Cancer Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <zip>06189</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Francois</last_name>
      <phone>+33 4 92 03 11 14</phone>
    </contact>
    <investigator>
      <last_name>Eric FRANCOIS, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier d'Orléans La Source</name>
      <address>
        <city>Orléans</city>
        <zip>45067</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Polyclinique Francheville</name>
      <address>
        <city>Perigueux</city>
        <zip>24004</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charles-Briac Levaché</last_name>
      <phone>+33 5 53 02 12 32</phone>
      <email>ch.levache@oncoradio24.com</email>
    </contact>
    <investigator>
      <last_name>Charles-Briac LEVACHE, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Jean</name>
      <address>
        <city>Perpignan</city>
        <zip>66046</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Faiza Khemissa Akouz</last_name>
      <phone>+33 4 68 61 66 33</phone>
      <email>faiza.khemisse@ch-perpignan.fr</email>
    </contact>
    <investigator>
      <last_name>Faiza KHEMISSA AKOUZ, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Pierre Bénite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU - Robert Debre</name>
      <address>
        <city>Reims</city>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier Bouche, MD, PhD</last_name>
      <phone>+33 3 26 78 71 69</phone>
      <email>obouche@chu-reims.fr</email>
    </contact>
    <investigator>
      <last_name>Olivier BOUCHE, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Romans</name>
      <address>
        <city>Romans</city>
        <zip>26100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Hôpital Victor Provo</name>
      <address>
        <city>Roubaix</city>
        <zip>59056</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Gregoire</name>
      <address>
        <city>Saint Gregoire</city>
        <zip>35768</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurent Miglianico</last_name>
      <phone>+33 2 99 54 09 49</phone>
      <email>lmiglianico@vivalto-sante.com</email>
    </contact>
    <investigator>
      <last_name>Laurent MIGLIANICO, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique Mutualiste de l'Estuaire</name>
      <address>
        <city>Saint Nazaire</city>
        <zip>44606</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine Ligeza Poisson</last_name>
      <phone>+33 2 72 27 54 02</phone>
      <email>catherine.ligeza@mla.fr</email>
    </contact>
    <investigator>
      <last_name>Catherine LIGEZA POISSON, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Saint Etienne - Hôpital Nord</name>
      <address>
        <city>Saint Priest en Jarez</city>
        <zip>42270</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Marc Phelip</last_name>
      <phone>+33 4 77 82 83 20</phone>
      <email>J.marc.phelip@chu-st-etienne.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-Marc PHELIP, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Paul Strauss</name>
      <address>
        <city>Strasbourg</city>
        <zip>67065</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meher Ben Abdelghani</last_name>
      <phone>+33 3 88 25 85 25</phone>
      <email>mbenabdelghani@strasbourg.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Meher BEN ABDELGHANI, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Intercommunal de Toulon</name>
      <address>
        <city>Toulon</city>
        <zip>83056</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 23, 2015</study_first_submitted>
  <study_first_submitted_qc>March 31, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 1, 2015</study_first_posted>
  <last_update_submitted>January 24, 2017</last_update_submitted>
  <last_update_submitted_qc>January 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Metastatic colorectal cancer</keyword>
  <keyword>cetuximab</keyword>
  <keyword>maintenance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

